Histamine and atopic eczema
- PMID: 2477978
- DOI: 10.2340/000155551447077
Histamine and atopic eczema
Abstract
Apart from increased production of immunoglobulin E antibodies and disturbed T-cell regulation, altered patterns of releasability of vasoactive mediators have been described in patients with atopic eczema. The best studied substance is histamine which is a classical inducer of pruritus in man. Elevated concentrations of histamine have been found in vivo in the skin and in the plasma of patients with atopic eczema especially during exacerbation of the disease. Similar findings have been described for other atopic diseases as extrinsic bronchial asthma. Histamine acts via characteristic receptors; symptoms as itch, wheal formation, mucus production, contraction of smooth muscle, tachycardia H2-effects include acid secretion in the stomach as well as the development of flush and itch reactions, blood pressure changes and cardiac arrhythmia. Of special interest is an inhibitory effect of histamine on lymphocyte reactions mediated via a H2-receptor. The existence of a new H3-receptor in the brain serving as autocrine feed-back inhibitor of histaminergic neurones has been established in the rat but not yet in man. In vitro an increased histamine releasability of peripheral leukocytes has been found after stimulation with a variety of different substances. The difference between patients with atopic eczema and normals is generally most pronounced after stimulation with anti-IgE. There is, however, a tendency towards an increased spontaneous histamine release compared to normals. The release reaction of histamine seems to occur more rapidly in atopics compared to normals.(ABSTRACT TRUNCATED AT 250 WORDS)
Similar articles
-
Altered releasability of vasoactive mediator secreting cells in atopic eczema.Acta Derm Venereol Suppl (Stockh). 1985;114:9-23. doi: 10.2340/00015555114923. Acta Derm Venereol Suppl (Stockh). 1985. PMID: 2408433 Review.
-
Recent studies of cutaneous nociception in atopic and non-atopic subjects.J Dermatol. 1999 Feb;26(2):77-86. doi: 10.1111/j.1346-8138.1999.tb03516.x. J Dermatol. 1999. PMID: 10091477 Review.
-
In vitro IgE eluation and histamine releasability from peripheral leukocytes of atopics and normals.J Dermatol Sci. 1991 Dec;2(6):413-21. doi: 10.1016/0923-1811(91)90005-i. J Dermatol Sci. 1991. PMID: 1726056
-
Pharmacophysiology of atopic dermatitis.Clin Rev Allergy. 1986 Feb;4(1):43-65. doi: 10.1007/BF02991187. Clin Rev Allergy. 1986. PMID: 3008974 Review.
-
Basophil mediator release in atopic dermatitis.J Invest Dermatol. 1993 Mar;100(3):305-9. doi: 10.1111/1523-1747.ep12469895. J Invest Dermatol. 1993. PMID: 7680056
Cited by
-
Mesenchymal Stem Cells and Atopic Dermatitis: A Review.Front Cell Dev Biol. 2020 May 14;8:326. doi: 10.3389/fcell.2020.00326. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 32478072 Free PMC article. Review.
-
Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice.Br J Pharmacol. 2004 May;142(2):374-80. doi: 10.1038/sj.bjp.0705754. Epub 2004 Apr 5. Br J Pharmacol. 2004. PMID: 15066908 Free PMC article.
-
IgE, mast cells, and eosinophils in atopic dermatitis.Clin Rev Allergy Immunol. 2011 Dec;41(3):298-310. doi: 10.1007/s12016-011-8252-4. Clin Rev Allergy Immunol. 2011. PMID: 21249468 Review.
-
Mast cells and immunological skin diseases.Clin Rev Allergy Immunol. 2007 Oct;33(1-2):144-55. doi: 10.1007/s12016-007-0029-4. Clin Rev Allergy Immunol. 2007. PMID: 18094953 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Research Materials